Estradiol and perimenopause: separating TikTok claims from trial data

What did @dr.meganlee actually say?

The core claim here is straightforward: low-dose estradiol starts at 0.25 mg for the gel and 0.025 mg/24 hours for the patch, and the gel tends to deliver lower serum estradiol levels than the patch does. She also says the gel produces more variable daily levels compared to the patch's steadier release.

She's speaking from clinical practice, not citing trials, which matters. Her framing is practical: start low, monitor serum levels, adjust based on how the individual absorbs the medication. She names specific dose thresholds, 0.75 mg gel and 0.05 mg patch, as the rough border between low and mid dosing in her own framework. She explicitly acknowledges individual variability, which is the right instinct even if the numbers she uses need some scrutiny.

Does the science back this up?

Largely yes, with some caveats. The dose ranges she describes are consistent with FDA-approved labeling and standard clinical practice. The claim that the gel produces more variable, peak-and-trough estradiol levels compared to the patch is well-documented.

A 2004 pharmacokinetic study by Nachtigall et al. in Fertility and Sterility confirmed that transdermal gel formulations produce higher peak serum estradiol in the hours after application, followed by a decline, while matrix patches maintain flatter serum concentrations over their 3-4 day wear cycle. A later comparative review by Canonico et al. (2010, Thrombosis and Haemostasis) also noted that delivery method affects not just levels but clinical outcomes, particularly around clotting risk, which is a reason delivery method selection actually matters clinically and isn't just a convenience question. The claim that gel generally delivers less estradiol than the patch at nominally comparable doses is also supported by pharmacokinetic data, though this depends heavily on application technique, skin site, and individual absorption.

What did they get wrong (or right)?

She got the core pharmacology right. Where things get fuzzy is the implied precision of her dose-tier framework. Calling 0.75 mg gel a "mid dose" is a clinical shorthand, not a regulatory or pharmacokinetic standard, and presenting it that way without that caveat could mislead viewers into thinking there's a universal threshold when there isn't one.

She does recover from this with the important qualifier that "doses are subjective to how you absorb these things," and she recommends monitoring serum estradiol levels in menopausal patients. That's the right call. The Menopause Society (formerly NAMS) 2022 position statement recommends individualizing hormone therapy based on symptom response and tolerability rather than targeting a specific serum level for most patients, so the emphasis on serum monitoring as a primary guide is slightly more aggressive than current consensus but not wrong for patients with absorption uncertainty.

One thing she glosses over: she says she uses gel first for patients she's worried about tolerating estrogen. This is reasonable clinical reasoning, but she doesn't explain why lower peak levels might matter for tolerability, which leaves viewers without the mechanism to evaluate the claim themselves.

What should you actually know?

If you're starting estradiol therapy, the delivery method genuinely affects your experience, not just your lab numbers. Patches are more consistent day to day. Gels give you more flexibility but require daily application and careful attention to skin-transfer risk, meaning other people or pets coming into contact with application sites.

The dose ranges she describes, 0.025 to 0.1 mg/24 hours for patches and 0.25 to 1.25 mg for gel, reflect real FDA-labeled options. But "low dose" for you depends on your symptoms, your baseline hormonal status, and how your skin absorbs the medication. A 2017 review by Stuenkel et al. in the Journal of Clinical Endocrinology and Metabolism reinforced that symptom relief, not hitting a serum number, is the primary goal for most menopausal patients. Serum monitoring is most useful when absorption is uncertain or symptoms don't match expectations. None of this should be taken as a personal dosing recommendation. This is a category where you need a clinician tracking your individual response over time.